Literature DB >> 17027227

The N-terminal SH2 domain of the tyrosine phosphatase, SHP-2, is essential for Jak2-dependent signaling via the angiotensin II type AT1 receptor.

Michael D Godeny1, Jacqueline Sayyah, Dannielle VonDerLinden, Melissa Johns, David A Ostrov, Jennifer Caldwell-Busby, Peter P Sayeski.   

Abstract

Previous work has suggested that the protein tyrosine phosphatase, SHP-2, may act to facilitate angiotensin II (Ang II)-mediated, Jak2-dependent signaling. However, the mechanisms by which this occurs are not known. Here, Ang II-mediated, Jak2-dependent signaling was analyzed in a fibroblast cell line lacking the N-terminal, SH2 domain of SHP-2 (SHP-2(Delta46-110)). While the SHP-2(Delta46-110) cells were capable of activating Jak2 tyrosine kinase, they were unable to facilitate AT1 receptor/Jak2 co-association, STAT activation and subsequent Ang II-mediated gene transcription when compared to wild type control cells. These data therefore suggested that the N-terminal SH2 domain of SHP-2 was acting to recruit Jak2 to the AT1 receptor signaling complex. We found that the N-terminal SH2 domain of SHP-2 binds Jak2 predominantly, but not exclusively at tyrosine 201. Mass spectrometry analysis confirmed that this tyrosine residue is in fact phosphorylated. When this tyrosine was converted to phenylalanine, the ability of Jak2 to activate subsequent downstream signaling events was reduced. In summary, we have identified a novel site of Jak2 tyrosine autophosphorylation; namely, tyrosine 201. Our data suggest that the N-terminal SH2 domain of SHP-2 binds this amino acid residue. The functional consequence of this interaction is to recruit Jak2 to the AT1 receptor signaling complex and in turn promote downstream Jak2-dependent signaling.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17027227     DOI: 10.1016/j.cellsig.2006.08.010

Source DB:  PubMed          Journal:  Cell Signal        ISSN: 0898-6568            Impact factor:   4.315


  17 in total

Review 1.  International Union of Basic and Clinical Pharmacology. XCIX. Angiotensin Receptors: Interpreters of Pathophysiological Angiotensinergic Stimuli [corrected].

Authors:  Sadashiva S Karnik; Hamiyet Unal; Jacqueline R Kemp; Kalyan C Tirupula; Satoru Eguchi; Patrick M L Vanderheyden; Walter G Thomas
Journal:  Pharmacol Rev       Date:  2015-10       Impact factor: 25.468

Review 2.  The Src homology 2 domain tyrosine phosphatases SHP-1 and SHP-2: diversified control of cell growth, inflammation, and injury.

Authors:  Z Z Chong; K Maiese
Journal:  Histol Histopathol       Date:  2007-11       Impact factor: 2.303

Review 3.  Multi-functionality of proteins involved in GPCR and G protein signaling: making sense of structure-function continuum with intrinsic disorder-based proteoforms.

Authors:  Alexander V Fonin; April L Darling; Irina M Kuznetsova; Konstantin K Turoverov; Vladimir N Uversky
Journal:  Cell Mol Life Sci       Date:  2019-08-19       Impact factor: 9.261

4.  Phosphorylation of Y372 is critical for Jak2 tyrosine kinase activation.

Authors:  Jacqueline Sayyah; Kavitha Gnanasambandan; Sushama Kamarajugadda; Shigeharu Tsuda; Jennifer Caldwell-Busby; Peter P Sayeski
Journal:  Cell Signal       Date:  2011-06-29       Impact factor: 4.315

5.  Redox-sensitive signaling by angiotensin II involves oxidative inactivation and blunted phosphorylation of protein tyrosine phosphatase SHP-2 in vascular smooth muscle cells from SHR.

Authors:  Fatiha Tabet; Ernesto L Schiffrin; Glaucia E Callera; Ying He; Guoying Yao; Arne Ostman; Kai Kappert; Nicholas K Tonks; Rhian M Touyz
Journal:  Circ Res       Date:  2008-06-19       Impact factor: 17.367

Review 6.  Fine-tuning of GPCR activity by receptor-interacting proteins.

Authors:  Stefanie L Ritter; Randy A Hall
Journal:  Nat Rev Mol Cell Biol       Date:  2009-12       Impact factor: 94.444

Review 7.  JAK redux: a second look at the regulation and role of JAKs in the heart.

Authors:  Mazen Kurdi; George W Booz
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-08-28       Impact factor: 4.733

8.  Disruption of Gpr45 causes reduced hypothalamic POMC expression and obesity.

Authors:  Jing Cui; Yi Ding; Shu Chen; Xiaoqiang Zhu; Yichen Wu; Mingliang Zhang; Yaxin Zhao; Tong-Ruei R Li; Ling V Sun; Shimin Zhao; Yuan Zhuang; Weiping Jia; Lei Xue; Min Han; Tian Xu; Xiaohui Wu
Journal:  J Clin Invest       Date:  2016-08-08       Impact factor: 14.808

Review 9.  The molecular regulation of Janus kinase (JAK) activation.

Authors:  Jeffrey J Babon; Isabelle S Lucet; James M Murphy; Nicos A Nicola; Leila N Varghese
Journal:  Biochem J       Date:  2014-08-15       Impact factor: 3.857

10.  Tyrosine 201 is required for constitutive activation of JAK2V617F and efficient induction of myeloproliferative disease in mice.

Authors:  Dongqing Yan; Robert E Hutchison; Golam Mohi
Journal:  Blood       Date:  2012-07-26       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.